Cooper Companies (NASDAQ:COO) Director Walter Rosebrough, Jr. Buys 3,000 Shares of Stock

The Cooper Companies, Inc. (NASDAQ:COO) Director Walter Rosebrough, Jr. acquired 3,000 shares of the firm’s stock in a transaction dated Monday, September 14th. The shares were purchased at an average cost of $54.29 per share, for a total transaction of $162,870.00. Following the completion of the acquisition, the director directly owned 20,000 shares in the company, valued at approximately $1,085,800. This represents a 17.65% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Cooper Companies Trading Down 1.8%

COO stock opened at $53.27 on Wednesday. The firm has a fifty day moving average price of $70.88 and a 200 day moving average price of $69.19. The Cooper Companies, Inc. has a fifty-two week low of $51.01 and a fifty-two week high of $89.83. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.73 and a current ratio of 1.22. The firm has a market cap of $10.13 billion, a PE ratio of 18.18, a price-to-earnings-growth ratio of 2.21 and a beta of 0.82.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.03. The company had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. Cooper Companies’s quarterly revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Sell-side analysts anticipate that The Cooper Companies, Inc. will post 4.53 earnings per share for the current fiscal year.

Cooper Companies declared that its Board of Directors has approved a share repurchase program on Wednesday, September 9th that allows the company to repurchase $3.00 billion in shares. This repurchase authorization allows the medical device company to repurchase up to 22.7% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s leadership believes its stock is undervalued.

Institutional Investors Weigh In On Cooper Companies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in COO. Root Financial Partners LLC grew its stake in Cooper Companies by 104.5% in the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after acquiring an additional 162 shares in the last quarter. Avalon Trust Co bought a new stake in shares of Cooper Companies during the second quarter valued at approximately $25,000. SJS Investment Consulting Inc. boosted its holdings in shares of Cooper Companies by 107.5% in the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 187 shares during the period. Elevation Wealth Partners LLC boosted its holdings in shares of Cooper Companies by 1,136.4% in the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 375 shares during the period. Finally, Continuum Advisory LLC bought a new position in Cooper Companies in the second quarter worth approximately $30,000. Institutional investors own 24.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on COO shares. BNP Paribas Exane lowered their price target on shares of Cooper Companies from $95.00 to $92.00 and set an “outperform” rating for the company in a report on Monday, June 8th. UBS Group reduced their price objective on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating on the stock in a research note on Thursday, September 10th. Stifel Nicolaus set a $70.00 price objective on Cooper Companies and gave the company a “buy” rating in a research report on Thursday, September 10th. JPMorgan Chase & Co. lowered their price objective on Cooper Companies from $71.00 to $58.00 and set a “neutral” rating for the company in a research note on Thursday, September 10th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Cooper Companies in a report on Friday, September 4th. Five equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $71.47.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Three Cooper Companies directors reported approximately $1.33 million in combined stock purchases. Paul A. Keel bought 4,701 shares for roughly $250,000, Lawrence Kurzius purchased 10,000 shares for $539,100, and Walter M. Rosebrough Jr. acquired 10,000 shares across two transactions for approximately $541,640. The purchases may indicate that company insiders view the recent selloff as excessive. SEC insider purchase filing
• Positive Sentiment: An analysis titled “A Little More Compelling At This Price” suggests COO’s valuation has become more attractive following the decline, potentially supporting interest from value-oriented investors. Seeking Alpha analysis
• Neutral Sentiment: Rosen Law Firm announced an investigation into potential securities claims involving allegations that Cooper Companies may have issued materially misleading business information. The announcement does not establish wrongdoing, but it adds legal and headline risk for shareholders. Rosen Law Firm announcement
• Negative Sentiment: Cooper Companies reduced fiscal 2026 adjusted EPS guidance to $4.51–$4.55 from $4.58–$4.66 and cut revenue guidance to $4.23–$4.25 billion from $4.29–$4.32 billion. The revisions reflect weaker-than-expected contact-lens demand, particularly at CooperVision. Insider Monkey report
• Negative Sentiment: Reports indicated that third-quarter results included U.S. channel inventory destocking and other negative surprises, contributing to the sharp decline in COO shares. Investors are likely focused on how quickly distributors normalize inventories and whether underlying demand improves. HBSS report

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.